This study is a phase 1/2 clinical trial to evaluate the safety and efficacy of administering
clusters of autologous dermal fibroblasts to subjects with periorbital wrinkles on both
If subjects who have signed the Informed consent form voluntarily are enrolled in this study,
they will be tested for eligibility during the screening period. Subjects will visit the
study site a total of 6 times while participating in this study. The subjects who meet the
inclusion/exclusion criteria will receive a total of one dose of the IP (Visit 3). Then, the
efficacy evaluation will be conducted at Visit 4 (Week 2), Visit 5 (Week 12), and Visit 6
(Week 24), and safety will also be evaluated at each visit.